FUJIFILM DIOSYNTH BIOTECHNOLOGIES ANNOUNCES PRESENTATION AT BIOTECH SHOWCASE 2018 EVENT
MORRISVILLE, N.C., Jan. 3, 2018 ‒ FUJIFILM Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organization (CDMO), is pleased to announce that Martin Meeson, President and COO of FUJIFILM Diosynth Biotechnologies U.S.A., is scheduled to present at EBD’s Biotech Showcase 2018 event during the 36th Annual J.P. Morgan Healthcare conference week in San Francisco, California. The presentation is scheduled to take place Tuesday, Jan. 9, 2018 at 3:00 PM PST. The presentation will be part of the Yosemite -B Track (Ballroom Level).
Mr. Meeson’s presentation will focus on FUJIFILM Diosynth Biotechnologies’ investment strategies to support the growth and expansion required to meet the global demands in the delivery of biologics, gene and cell therapies.
The Biotech Showcase 2018 will take place at the Hilton San Francisco Union Square located at 333 O'Farrell Street – Ballroom Level, San Francisco, California 94102.
FUJIFILM Diosynth Biotechnologies an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Billingham and Redcar, UK, RTP, North Carolina and College Station, Texas. FUJIFILM Diosynth has over twenty five years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™ cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation. For more information, go to: www.fujifilmdiosynth.com
FUJIFILM Holdings Corporation, Tokyo, Japan delivers innovative solutions across a broad range of businesses, derived from the depth of knowledge of core and fundamental technologies required for the complex design, engineering and manufacturing of photographic film. These business fields include medical digital radiography, women's health, endoscopy, ultrasound, medical informatics, CDMO biopharmaceuticals, regenerative medicine, pharmaceuticals and cosmetics. Other businesses include graphic systems, highly functional materials, optical devices, imaging, digital imaging and document products. In the year ended March 31, 2017, the company had global revenues of $20.7 billion, at an exchange rate of 112 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com
All product and company names herein may be trademarks of their registered owners.
Liza M. Rivera
FUJIFILM Diosynth Biotechnologies